Read by QxMD icon Read

Annals of Pharmacotherapy

Laura T Pizzi, Katherine M Prioli, Lynn Fields Harris, Elizabeth Cannon-Dang, Marie Marthol-Clark, Matt Alcusky, Megan McCoy, Jason J Schafer
BACKGROUND: Vaccination is the best way to prevent pneumococcal disease (PD), but 40% of older adults remain unvaccinated nationwide, with even greater nonvaccination rates among African Americans (AAs). Prior studies suggest that insufficient knowledge contributes to low vaccination rates. The Pharmacists' Pneumonia Prevention Program (PPPP) was designed to improve older adults' knowledge about PD and pneumococcal vaccination (PV). OBJECTIVE: To measure PPPP's effect on knowledge and activation in a predominantly AA population and determine program costs...
November 1, 2017: Annals of Pharmacotherapy
Babgaleh B Timbo, Stuart J Chirtel, John Ihrie, Taiye Oladipo, Loy Velez-Suarez, Vickery Brewer, Robert Mozersky
BACKGROUND: The Food and Drug Administration (FDA)'s Center for Food Safety and Applied Nutrition (CFSAN) oversees the safety of the nation's foods, dietary supplements, and cosmetic products. OBJECTIVE: To present a descriptive analysis of the 2004-2013 dietary supplement adverse event report (AER) data from CAERS and evaluate the 2006 Dietary Supplements and Nonprescription Drug Consumer Protection Act as pertaining to dietary supplements adverse events reporting...
November 1, 2017: Annals of Pharmacotherapy
Patrice Simard, Nancy Presse, Louise Roy, Marc Dorais, Brian White-Guay, Agnès Räkel, Sylvie Perreault
BACKGROUND: Metformin presents better survival rates than other oral antidiabetics in the treatment of type 2 diabetes. However, these benefits may be dampened by inadequate treatment adherence. OBJECTIVE: We aimed to investigate the relationship between adherence level to metformin therapy and all-cause mortality over 10 years in incident metformin users. METHODS: A nested case-control study was conducted using a large cohort of beneficiaries of the Quebec public drug insurance plan, aged 45 to 85 years, who initiated metformin between 2000 and 2009...
November 1, 2017: Annals of Pharmacotherapy
Seth T Howell, Leah A Cardwell, Steven R Feldman
OBJECTIVE: Guselkumab, an anti-interleukin-23 monoclonal antibody was recently approved for the treatment of patients with moderate-to-severe plaque psoriasis. This article will review the available phase II and phase III guselkumab clinical trial data. DATA SOURCES: A PubMed search was conducted using the terms guselkumab, interleukin-23, psoriasis, adalimumab, and ustekinumab (January 2014 to August 2017). STUDY SELECTION AND DATA EXTRACTION: Articles detailing the results of phase II and phase III clinical trials were selected for review...
November 1, 2017: Annals of Pharmacotherapy
Hayretdin Koklu, Tuğrul Pürnak, Nomingerel Tseveldorj, Ege Altan, Halis Şimşek
No abstract text is available yet for this article.
November 1, 2017: Annals of Pharmacotherapy
Elias B Chahine, Denise Kelley, Lindsey M Childs-Kean
OBJECTIVES: To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection. DATA SOURCES: A literature search through PubMed was conducted (August 2010 to August 2017) using the terms GS-9857, voxilaprevir, and NS3/4A protease inhibitor. STUDY SELECTION/DATA EXTRACTION: Studies of sofosbuvir/velpatasvir/voxilaprevir were identified. DATA SYNTHESIS: Sofosbuvir/velpatasvir/voxilaprevir is indicated for adult patients with chronic HCV without cirrhosis or with compensated cirrhosis who have (1) genotype 1 through 6 and have previously been treated with an NS5A inhibitor or (2) genotype 1a or 3 and have previously been treated with sofosbuvir without an NS5A inhibitor...
November 1, 2017: Annals of Pharmacotherapy
Angela Cheng-Lai, Jessica Snead, Christina Ng, Caroline Verges, Philip Chung
BACKGROUND: Little information is available regarding prescribers' adherence rate to the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline, especially that from a teaching versus a nonteaching setting. OBJECTIVES: We aim to evaluate adherence rates to the 2013 ACC/AHA cholesterol guideline in a teaching versus a nonteaching practice site. In addition, the impact of a pharmacist-led seminar on adherence rate to the guideline was assessed...
November 1, 2017: Annals of Pharmacotherapy
Stephanie Cheung, Sannifer Hoi, Olavo Fernandes, Jin Huh, Sara Kynicos, Laura Murphy, Donna Lowe
BACKGROUND: Dangerous abbreviations on the Institute for Safe Medication Practices Canada's "Do Not Use" list have resulted in medication errors leading to harm. Data comparing rates of use of dangerous abbreviations in paper and electronic medication orders are limited. OBJECTIVE: To compare rates of use of dangerous abbreviations from the "Do Not Use" list, in paper and electronic medication orders. Secondary objectives include determining the proportion of patients at risk for medication errors due to dangerous abbreviations and the most commonly used dangerous abbreviations...
November 1, 2017: Annals of Pharmacotherapy
Sami Alaya, Ali Mofredj, Nicolas Darmon, Karima Tassaioust, Afef Mrabet
No abstract text is available yet for this article.
November 1, 2017: Annals of Pharmacotherapy
Rebecca M Hoover, John Erramouspe
OBJECTIVE: To review and summarize topical oxymetazoline's pharmacology, pharmacokinetics, efficacy, safety, cost, and place in therapy for persistent redness associated with erythematotelangiectatic rosacea. DATA SOURCES: Literature searches of MEDLINE (1975 to September 2017), International Pharmaceutical Abstracts (1975 to September 2017), and Cochrane Database (publications through September 2017) using the terms rosacea, persistent redness, α -agonist, and oxymetazoline...
November 1, 2017: Annals of Pharmacotherapy
Hoyle Whiteside, Arpita Gandhi, Germame Ajebo, Locke J Bryan
No abstract text is available yet for this article.
November 1, 2017: Annals of Pharmacotherapy
Julie A Murphy, Erica A Sheridan
OBJECTIVE: To summarize and evaluate the existing literature regarding medications to treat opioid-induced constipation (OIC) in patients with chronic noncancer pain (CNCP). DATA SOURCES: PubMed, EMBASE, and Web of Science were searched using the following terms: constipation, opioid, chronic, pain, noncancer, nonmalignant, methylnaltrexone, alvimopan, lubiprostone, naloxegol, and naldemedine. STUDY SELECTION AND DATA EXTRACTION: The search was limited to randomized controlled trials reporting human outcomes...
October 1, 2017: Annals of Pharmacotherapy
Shardool Patel, Jan M Carmichael, Janice M Taylor, Mark Bounthavong, Diana T Higgins
BACKGROUND: Chronic opioid therapy-clinical reminder (COT-CR) is a decision support tool to prompt providers to carefully assess patients prescribed chronic opioids. This tool was developed to address inappropriate opioid prescribing. OBJECTIVE: To determine COT-CR's impact on reducing morphine equivalent monthly dose (MEMD) and risk index for overdose or serious prescription opioid-induced respiratory depression (RIOSORD) values in veterans receiving chronic opioids...
October 1, 2017: Annals of Pharmacotherapy
Michael P Lorenzo, Lindsay MacConaghy, Christopher D Miller, Gregory Meola, Luke A Probst, Brian Pratt, Jeff Steele, Robert W Seabury
BACKGROUND: Severe sepsis and septic shock represent common presentations in the emergency department (ED) and have high rates of mortality. Guideline-recommended goals of care have been shown to benefit these patients, but can be difficult to provide. OBJECTIVE: To determine whether the use of a premixed bag consisting of 2 g cefepime and 1 g vancomycin in 1000 mL of normal saline increases the probability of patients receiving Surviving Sepsis Campaign (SSC) recommendations for the initiation of antimicrobials and fluid challenge...
October 1, 2017: Annals of Pharmacotherapy
Retha Rajah, Mohamed Azmi Hassali, Ching-Jou Lim
BACKGROUND: Health care practitioners carry a tremendous responsibility to differentiate the varying need of information and customized communication according to a patient's health literacy (HL) level. OBJECTIVES: To assess and compare the HL communication practices among physicians, pharmacists, and nurses serving at public hospitals in Penang, Malaysia. METHODS: A pretested, self-administered questionnaire was used to collect data from study participants of 6 public hospitals using stratified sampling...
October 1, 2017: Annals of Pharmacotherapy
T David Marr, Nicole R Pinelli, Jamie A Jarmul, Kayla M Waldron, Stephen F Eckel, Jonathan D Cicci, Jill S Bates, Lindsey B Amerine
BACKGROUND: Pharmacy practice models that foster pharmacists' accountability for medication-related outcomes are imperative for the profession. Comprehensive medication management (CMM) is an opportunity to advance patient care. OBJECTIVE: The objective of this study was to evaluate the impact of a CMM practice model in the acute care setting on organizational, patient, and financial outcomes. METHODS: Three adult service lines focused on at-risk patients identified using internal risk stratification methodology were implemented...
October 1, 2017: Annals of Pharmacotherapy
Herbert L DuPont, Jasmohan S Bajaj
No abstract text is available yet for this article.
October 1, 2017: Annals of Pharmacotherapy
David A Bookstaver, Kimberly Sparks, Brandon S Pybus, Dustin K Davis, Sean R Marcsisin, Jason C Sousa
BACKGROUND: There is no established method for monitoring the anticoagulant effects of apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has been shown, with r(2) ranging from 0.88 to 0.99. However, there are minimal data in patients receiving apixaban 5 mg twice daily or rivaroxaban 20 mg once daily. OBJECTIVE: To evaluate the anti-Xa activity and serum levels at those doses and compare the trough anti-Xa activity. METHODS: This was a single-center prospective study,approved by the institutional review board...
October 1, 2017: Annals of Pharmacotherapy
Jacob A Kanter, Neeraj Chhabra, Michele Zell-Kanter
No abstract text is available yet for this article.
October 1, 2017: Annals of Pharmacotherapy
Katherine Fuller, Stephanie Malecki, Lisa Anselmo, Matthew E Borrego, Bernadette Jakeman, Allison Burnett
BACKGROUND: No randomized controlled trials have investigated enoxaparin once versus twice daily for venous thromboembolism (VTE) treatment in cancer patients. OBJECTIVE: To compare the safety and efficacy of enoxaparin 1 mg/kg twice daily versus enoxaparin 1.5 mg/kg/day for the treatment of acute VTE in cancer patients. METHODS: This was a single-center, retrospective, observational cohort study. Adults with active cancer and an acute VTE were included...
October 1, 2017: Annals of Pharmacotherapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"